JPRN-UMIN000039608
Recruiting
未知
Analysis of bone microstructure using high-resolution peripheral quantitative computed tomography (HR-pQCT) in patients with primary hyperparathyroidism - Analysis of bone microstrucure using HR-pQCT in primary hyperparathyroidism
agasaki University Hospital0 sites50 target enrollmentApril 1, 2020
ConditionsPrimary hyperparathyroidism
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Primary hyperparathyroidism
- Sponsor
- agasaki University Hospital
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients treated at present or within 12 months with teriparatide. 2\. Patinets administered with steroids. 3\. Patients compricated with malignancy. 4\. Pregnant or brest feeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Analysis of bone microstructure using second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) in patients with primary aldosteronismPrimary aldosteronismJPRN-UMIN000038531agasaki University Hospital100
Recruiting
Not Applicable
Analysis of bone microstructure using second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) in patients with Cushing syndromeJPRN-UMIN000038532agasaki University Hospital50
Active, not recruiting
Phase 1
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboOsteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. Postmenopausal women with a diagnosis of osteopenia (T score between –2.5 and –1.0 based on the World Health Organization classification) may also be at risk of fracture.MedDRA version: 7.0 Level: PT Classification code 10031285EUCTR2005-003033-41-GBProcter & Gamble Technical Centres Limited156
Active, not recruiting
Not Applicable
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboEUCTR2005-003033-41-DEProcter & Gamble Technical Centres Limited156
Active, not recruiting
Not Applicable
Bone Histomorphometry, Microarchitecture and Matrix Structure and Properties in Patients Receiving Long-term Risedronate Treatment - IMPACT Biopsy RegistryEUCTR2006-004840-21-ATsanofi-aventis Netherlands B.V.20